LINC01801: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01801

NCBI ID: G400685

LINC01801

Other Name(s): long intergenic non-protein coding RNA 1801 | Long intergenic non-protein coding RNA 1801

LINC01801: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC01801 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure, length, and presence in different tissues, which has caught the attention of researchers. LINC01801 has been shown to play a critical role in various biological processes, including cell signaling, development, and disease. Its potential as a drug target or biomarker has made it an attractive target for research in the field of molecular medicine.

Structure and Function

The structure of LINC01801 is unique, as it has a length of 292 amino acids and 19 unique coding regions. It is characterized by the presence of a stem-loop and a rich variety of post-transcriptional modifications, such as RNA editing and processing. LINC01801 is expressed in various tissues and cells, including brain, heart, liver, and cancer cells. It has been shown to be involved in various signaling pathways, including the PI3K/Akt signaling pathway, which is involved in cell signaling and survival.

LINC01801 has been shown to play a critical role in the PI3K/Akt signaling pathway in various organisms, including mammals. It has been shown to regulate the activity of the protein kinase Akt, which is involved in the translation of RNA into protein. LINC01801 has has also been shown to interact with the protein casein kinase (CK) 2, which is involved in the regulation of cellular signaling pathways.

In addition to its role in cell signaling, LINC01801 has also been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. It has been shown to play a critical role in the regulation of cell cycle progression , and has been shown to be involved in the regulation of the G1/S transition, which is involved in cell growth and development. LINC01801 has also been shown to be involved in the regulation of cell apoptosis, which is the process by which cells die as a result of various stimuli, including stress and disease.

As a potential drug target, LINC01801 has been shown to have a unique mechanism of action, which makes it an attractive target for small molecule inhibitors. LINC01801 has been shown to have a high degree of homogeneity, which makes it easier to develop and refine small molecule inhibitors. Its unique structure and function also make it an attractive target for small molecule inhibitors, as it is less likely to have similar effects to natural compounds.

As a potential biomarker, LINC01801 has been shown to have a unique expression pattern in various tissues and cells. Additionally, its expression patterns have been shown to be different between healthy and diseased tissues, which makes it an attractive target for diagnostic biomarkers. patterns have been shown to be regulated by various factors, including disease-specific genetic and environmental factors. This makes its expression patterns more responsive to therapeutic interventions.

Methods

To determine the potential of LINC01801 as a drug target, researchers have used various techniques, including RNA interference, overexpression, and biochemical assays. They have shown that LINC01801 can be successfully overexpressed in various cell types, including cancer cells, and that it has a unique mechanism of action, which makes it an attractive target for small molecule inhibitors.

In addition to its potential as a drug target, LINC01801 has also been shown to be a potential biomarker in various diseases, including cancer. Researchers have used various techniques, including qRT-PCR, to detect the expression of LINC01801 in various tissues

Protein Name: Long Intergenic Non-protein Coding RNA 1801

The "LINC01801 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01801 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets